Insurance Cover for Mental Illness in India, Now Reality

M Neelam Kachhap
M Neelam Kachhap
· 2 min read
mental health

The Insurance Regulatory Development Authority of India (IRDA) has issued a circular to all insurers to include mental health in their insurance scheme. Drawing reference to the Mental Healthcare Act, 2017 which has come into effect from May 2018, IRDA has asked the insurers to follow the same. As per Sec 21(4) of the said Act, every insurer shall make provision for medical insurance for treatment of mental illness on the same basis as is available for treatment of physical illness.

The IRDA has directed all insurance companies to comply with the aforesaid provisions of the Mental Healthcare Act, 2017 with immediate effect.

The insurance sector has welcomed the directive. Jyoti Punja, Chief Operating Officer and Customer Officer, Cigna TTK Health Insurance Company said, “Insurance of mental health is a progressive step in right direction. This will ensure a life of dignity to those who have mental health issues. We believe it will certainly create awareness, acceptance, and inclusion when it comes to mental illness as any other ailment, while bringing mental health disorders at par with physical illnesses will ‘normalize’ diagnoses, reducing associated myths and stigma. At Cigna TTK, we focus on the health and wellness of our customers we serve and we welcome this step to drive a robust health and well-being ecosystem.”

“Including mental health in health insurance coverage is an important and progressive step,” said Soumya Swaminathan, Deputy Director-General Programmes, WHO.

However, it is not clear how the insurance package will work for mental health as health insurance in India mostly covers hospitalisation where as mental health needs more of OPD and consultation along with long term drug treatment.

Read Next

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk
DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 
News
June 11, 2026

DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to […]
Article by: IMT News Desk
Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India
News
June 11, 2026

Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India

Oval Advanced Fertility Care and Merck Specialities Private Limited, the Indian healthcare arm of Merck KGaA, Darmstadt, Germany and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MOU).   India’s IVF market, valued at approximately USD 2.35 billion in 2024, is projected […]
Article by: IMT News Desk
Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global
News
June 11, 2026

Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global

Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in its ongoing Series B funding round to expand its hospital-linked genomics laboratory network globally and scale its AI-powered precision oncology platform, OncoTwin. The latest funding round, which follows a first close of ₹90 crore co-led by Ashish Kacholia and Lashit Sanghvi with participation from existing […]
Article by: IMT News Desk